Item 1.01. Entry into a Material Definitive Agreement.

As previously reported in January 2021, Myomo, Inc. (the "Company") entered into an Equity Joint Venture Contract with Beijing Ryzur Medical Investment Co., Ltd. ("Ryzur Medical"), a medical device manufacturer based in Beijing, China, to form a joint venture (the "JV") to manufacture and sell the Company's current and future products in greater China, including Hong Kong, Macau and Taiwan (the "JV Agreement"). On December 30, 2021 and made effective retroactively to December 29, 2021 (the "Effective Date"), the Company entered into an amended and restated JV Agreement (as amended and restated, the "Amended JV Agreement"), a Technology License Agreement and a Trademark License Agreement. The Amended JV Agreement added Wuxi Chinaleaf Rehabilitation Industry Equity Investment Fund (Limited Partnership) ("Chinaleaf") as a party to hold an equity interest in the JV. The Company retained its 19.9% equity interest in the JV. In addition, the Amended JV Agreement modified certain governance matters, including eliminating certain consent rights from the original JV Agreement favor of the Company, as described in the Amended JV Agreement. The Amended JV Agreement also fixed the per-unit price for MyoPro Control System units, the purchase of which is required to meet the minimum annual guaranteed payments to Myomo as defined in the Amended JV Agreement,

The Technology License Agreement is a ten-year agreement to license the Company's intellectual property and purchase MyoPro Control System units from the Company. Under the Technology License Agreement, the Company is entitled to receive an upfront license fee of $2.7 million, Payment of the first installment of $0.2 million is due within 30 days of the Effective Date, the proceeds from which the Company will contribute to the registered capital of the JV ("Myomo Contribution"). Payment of the remainder of the license fee is due within 30 days from the date of the Myomo Contribution, after receipt of which the Company shall commence the transfer of technology.

The Trademark License Agreement provides for the license of certain of the Company's trademarks for use by the JV in its territory of operation.

The foregoing summaries of the terms of the Amended JV Agreement, the Technology License Agreement and the Trademark License Agreement do not purport to be complete and are qualified in their entirety by reference to the such agreements, copies of which will be filed with the Company's next Annual Report on Form 10-K for the year ended December 31, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses